Hangzhou Nuojin Biotechnology

Hangzhou Nuojin Biotechnology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on developing next-generation immune cell therapies for solid tumors. The company utilizes its proprietary technology platforms to develop Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies specifically engineered to penetrate and function within the complex microenvironment of solid cancers. Its lead program, NJ-C01, is a CAR-T therapy targeting Claudin 18.2, which has shown promising results in early clinical trials for gastric and pancreatic cancers. Additionally, the company is advancing TCR-T candidates targeting NY-ESO-1 for sarcomas and other CAR-T programs for liver cancer. Nuojin Biotech aims to address significant unmet medical needs in oncology through its innovative cellular immunotherapy pipeline.